This Article Full Text Full Text (PDF) Supplementary Data Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Chemnitz, J. M. Articles by Schultze, J. L. Search for Related Content PubMed PubMed Citation Articles by Chemnitz, J. M. Articles by Schultze, J. L.

Prostaglandin E₂ Impairs CD4⁺ T Cell Activation by Inhibition of lck: Implications in Hodgkin's Lymphoma

¹ Molecular Tumor Biology and Tumor Immunology, Department of Internal Medicine I, University of Cologne, Cologne, Germany and ² Abramson Cancer Research Center, University of Pennsylvania, Philadelphia, Pennsylvania

Requests for reprints: Joachim L. Schultze, Molecular Tumor Biology and Tumor Immunology, Department of Internal Medicine I, University of Cologne, Joseph-Stelzmann-Str. 9, 50924 Cologne, Germany. Phone: 49-221-478-4489; Fax: 49-221-478-5912; E-mail: joachim.schultze{at}uk-koeln.de.

Many tumors, including Hodgkin's lymphoma, are associated with decreased cellular immunity and elevated levels of prostaglandin E₂ (PGE₂), a known inhibitor of CD4⁺ T cell activation, suggested to be involved in immune deviation in cancer. To address the molecular mechanisms tumor-derived PGE₂ might have on primary human CD4⁺ T cells, we used a whole genome-based transcriptional approach and show that PGE₂ severely limited changes of gene expression induced by signaling through the T cell receptor and CD28. This data suggests an interference of PGE₂ at an early step of T cell receptor signaling: indeed, PGE₂ stimulation of T cells leads to inactivation of lck and reduced phosphorylation of ZAP70. Antiapoptotic genes escaped PGE₂-induced inhibition resulting in partial protection from apoptosis in response to irradiation or Fas-mediated signaling. As a functional consequence, PGE₂-treated CD4⁺ T cells are arrested in the cell cycle associated with up-regulation of the cyclin/cyclin-dependent kinase inhibitor p27^kip1. Most importantly, CD4⁺ T cells in Hodgkin's lymphoma show similar regulation of genes that were altered in vitro by PGE₂ in T cells from healthy individuals. These data strongly suggest that PGE₂ is an important factor leading to CD4⁺ T cell impairment observed in Hodgkin's lymphoma. (Cancer Res 2006; 66(2): 1114-22)

This article has been cited by other articles:

				A. Popov, J. Driesen, Z. Abdullah, C. Wickenhauser, M. Beyer, S. Debey-Pascher, T. Saric, S. Kummer, O. Takikawa, E. Domann, et al. Infection of Myeloid Dendritic Cells with Listeria monocytogenes Leads to the Suppression of T Cell Function by Multiple Inhibitory Mechanisms J. Immunol., October 1, 2008; 181(7): 4976 - 4988. [Abstract] [Full Text] [PDF]

				J. M. Chemnitz, D. Eggle, J. Driesen, S. Classen, J. L. Riley, S. Debey-Pascher, M. Beyer, A. Popov, T. Zander, and J. L. Schultze RNA fingerprints provide direct evidence for the inhibitory role of TGF{beta} and PD-1 on CD4+ T cells in Hodgkin lymphoma Blood, November 1, 2007; 110(9): 3226 - 3233. [Abstract] [Full Text] [PDF]

				S. Classen, T. Zander, D. Eggle, J. M. Chemnitz, B. Brors, I. Buchmann, A. Popov, M. Beyer, R. Eils, S. Debey, et al. Human Resting CD4+ T Cells Are Constitutively Inhibited by TGFbeta under Steady-State Conditions J. Immunol., June 1, 2007; 178(11): 6931 - 6940. [Abstract] [Full Text] [PDF]

				M. Cronin, C. Sangli, M.-L. Liu, M. Pho, D. Dutta, A. Nguyen, J. Jeong, J. Wu, K. C. Langone, and D. Watson Analytical Validation of the Oncotype DX Genomic Diagnostic Test for Recurrence Prognosis and Therapeutic Response Prediction in Node-Negative, Estrogen Receptor-Positive Breast Cancer Clin. Chem., June 1, 2007; 53(6): 1084 - 1091. [Abstract] [Full Text] [PDF]

				M. S. von Bergwelt-Baildon, A. Popov, T. Saric, J. Chemnitz, S. Classen, M. S. Stoffel, F. Fiore, U. Roth, M. Beyer, S. Debey, et al. CD25 and indoleamine 2,3-dioxygenase are up-regulated by prostaglandin E2 and expressed by tumor-associated dendritic cells in vivo: additional mechanisms of T-cell inhibition Blood, July 1, 2006; 108(1): 228 - 237. [Abstract] [Full Text] [PDF]